PharmaEngine

NEW DRUGS FOR THE TREATMENT OF CANCER

PharmaEngine
We Race With You

CANCER TREATMENT PRODUCTS

ONIVYDE
A Revolutionary Durg

DISCOVER ONIVYDE

History<br>
&<br>
Milestones<br> — History
&
Milestones

Onivyde

PEP07: A novel, brain penetrant oral Chk1 inhibitor for the treatment of AML and MCL (6th Annual DDR Inhibitors Summit 2023)

Onivyde® regimen (NALIRIFOX) demonstrated statistically significant improvement in overall survival in 1L PDAC(Supplementary information)

Positive Topline Results from Phase III NAPOLI-3 trial of ONIVYDE® regimen (NALIRIFOX) as a first-line treatment for previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)

Events & Presentations

Go To Top